JOHNSON & JOHNSON (JNJ.DE) Stock Price, Forecast & Analysis
FRA:JNJ • US4781601046
JNJ.DE Key Statistics, Chart & Performance
The current stock price of JNJ.DE is 205.6 EUR. In the past month the price increased by 10.47%. In the past year, price increased by 32.92%.
JNJ.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to JNJ.DE. When comparing the yearly performance of all stocks, JNJ.DE is one of the better performing stocks in the market, outperforming 84.56% of all stocks.
JNJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE. JNJ.DE scores excellent on profitability, but there are some minor concerns on its financial health.
JNJ.DE Financial Highlights
Over the last trailing twelve months JNJ.DE reported a non-GAAP Earnings per Share(EPS) of 9.19. The EPS increased by 8.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.26% | ||
| ROA | 13.03% | ||
| ROE | 31.69% | ||
| Debt/Equity | 0.55 |
JNJ.DE Forecast & Estimates
32 analysts have analysed JNJ.DE and the average price target is 197.22 EUR. This implies a price decrease of -4.08% is expected in the next year compared to the current price of 205.6.
For the next year, analysts expect an EPS growth of 7.88% and a revenue growth 7.21% for JNJ.DE
JNJ.DE Ownership
JNJ.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.41 | 191.073B | ||
| SAN | SANOFI | 9.41 | 190.807B | ||
| 1SAN | SANOFI | 9.24 | 188.634B | ||
| MRK | MERCK KGAA | 14.91 | 55.608B | ||
| UNC | UCB SA | 27.56 | 55.124B | ||
| UCB | UCB SA | 26.85 | 55.085B | ||
| 1BAYN | BAYER AG-REG | 9.38 | 45.039B | ||
| BAYN | BAYER AG-REG | 8.94 | 44.774B | ||
| IPN | IPSEN | 13.83 | 13.259B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 11.016B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About JNJ.DE
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138200
Phone: 17325242455
JOHNSON & JOHNSON / JNJ.DE FAQ
Can you describe the business of JOHNSON & JOHNSON?
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
What is the stock price of JOHNSON & JOHNSON today?
The current stock price of JNJ.DE is 205.6 EUR. The price decreased by -1.39% in the last trading session.
Does JNJ stock pay dividends?
JOHNSON & JOHNSON (JNJ.DE) has a dividend yield of 2.11%. The yearly dividend amount is currently 4.37.
How is the ChartMill rating for JOHNSON & JOHNSON?
JNJ.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the expected growth for JNJ stock?
The Revenue of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 7.21% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for JOHNSON & JOHNSON?
JOHNSON & JOHNSON (JNJ.DE) currently has 138200 employees.
Who owns JOHNSON & JOHNSON?
You can find the ownership structure of JOHNSON & JOHNSON (JNJ.DE) on the Ownership tab.